Programs and Projects

Prostate Cancer Clinical Trials - Mayo Clinic
Agent: Exisulind (Sulindac Sulfone)
Contact: Brad Leibovich, M.D.
DCP Program Director: Howard Parnes, M.D.

The purpose of this study is to evaluate the potential of Sulindac Sulfone as a chemopreventive agent for prostate cancer. Men with a diagnosis of prostate cancer who are considering surgical removal of the prostate gland (prostatectomy) may be eligible to participate in this study. Those taking part in the study will receive either Sulindac Sulfone or no agent (control group) for several weeks immediately before prostate surgery. The study is now closed to accrual.

[This is a phase 2 prospective, non-randomized concurrently controlled trial of the novel agent, Exisulind, administered for 4 weeks in the presurgical period prior to prostatectomy in men with localized prostate cancer. The primary endpoint is modulation of the apoptotic index in prostatic epithelium-normal, HGPIN and cancer.]